uBiome: Ethical Lapse or Not?
By Judy Stone,
Scientific American
| 07. 25. 2013
uBiome’s CEO, Jessica Richman, seems to me to be a great saleswoman who also excels at sounding innocent and playing the misunderstood victim in the ethical controversy surrounding her company. I think this was well illustrated in her recent guest blog in Scientific American with Dr. Zachary Apte, co-founder and Chief Scientific Officer of uBiome. The picture is a little less rosy if you look back at the origins and history of the discussions about her company’s perceived ethical lapses.
I was intending to write about uBiome before this, as I was disturbed by Richman’s appearance at TEDMED. Admittedly, I was already put off by her telling twitter handle of “@venturejessica.” Her hubris was further evidenced by the title of her TEDMED talk, “Could a citizen scientist win a Nobel Prize?” Fortunately, her talk was a bit more restrained, though still touting the potential of her as yet untested product.
Richman and Apte’s recent blog has shown that they seem to have learned little from the heated discussions about uBiome. Their business is part of the UCSF’s Quantitative Biosciences Institute...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...